A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06410293 And Adalimumab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms REFLECTIONS; REFLECTIONS B538-02
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 05 Jan 2017 Primary endpoint has been met. (Number of Participants With an American College of Rheumatology 20% (ACR20) Response), as per a Pfizer media release.
- 27 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2017.